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Identification of multiple novel HIV-specific T-cell epitopes using HLA-associated HIV 
polymorphisms
Figure 2 Comparison of PBMC counts and viability
Frozen PBMCs were counted on the Vi-Cell XR after an overnight rest in 10 mL of 10% HI-FCS/RPMI at 37 C. The PBMC
yields recovered after thawing were low (median = 9%) but the majority of samples had a high proportion of viable
cells (median = 79%).
Figure 1 Summary of epitope identification, selection and IFN-γ ELISpot assay
Potential sites of HIV-adaptation to immune pressure were identified using the ‘Epi-pred’ prediction programme in a
cohort of 800 anti-retroviral naïve individuals. IFN-γ responses to the predicted epitopes were investigated in a subset
of these individuals with the ELISpot assay.
INTRODUCTION
Cytotoxic CD8 T-cells (CTLs) recognise antigenic peptides that are presented in the context of class I human leukocyte
antigens (HLA). The high degree of polymorphism in the HLA molecules enables the binding of peptides from a
number of infectious pathogens. The human immunodeficiency virus type-1 (HIV-1) selects for mutations in CTL
epitopes which can affect binding to the HLA molecule, recognition by the T-cell receptor (TCR) or intracellular
processing; and as a consequence, the virus evades detection by the immune system1. However, the pathways of viral
escape can be predicted by the HLA-alleles carried in an individual. At a population level, knowledge of the most
frequently occurring alleles could therefore be used to predict targets of CTLs that are immunologically relevant in
vivo2.
We have previously investigated HIV adaptation in response to immune pressure in a cohort of 800 anti-retroviral
naïve individuals from two geographically distinct populations (United States of America and Western Australia)
predominantly infected with the subtype B virus3. Using whole genome HIV sequencing and high resolution HLA
genotyping, a consensus sequence was generated and scanned with the ‘Epi-pred’ epitope prediction programme to
identify putative in vivo selection of CD8 T-cell targes (non-adapted) as well as HLA-adapted variants capable of
inducing a de novo immune response (adapted epitopes). Here we investigate the immunologic relevance of the
predicted HIV-HLA associations ex vivo in a subset of individuals from the USA cohort.
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Figure 3 Complex patterns of escape identified in the ELISpot assay
The creation of a variant resulted in the abrogation of the response as shown in A. Non-classical patterns of
escape were also identified wherein the adapted epitope elicited higher (B) or similar (C) IFN-γ responses in
comparison to the non-adapted epitope. The epitope used in the ELISpot assay is highlighted in bold; the non-
adapted and adapted amino acid residues are underlined.
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METHODS
RESULTS
IFN-γ responses were detected in 267 of the 291 samples with sufficient PBMCs to test the predictions. Amongst the
267 individuals, 54.3% were classified as responders (at least one response ≥100 SFUs/106 PBMCs) with an average
response of 353 SFUs/106 PBMCs.
CONCLUSIONS
Of the HIV-HLA associations identified, 475 were tested in the IFN-γ ELISpot assay using a set of criteria that took
into consideration the limited cellular material available. Ten novel epitopes were identified where the predicted
HLA-restriction matched the genotype of the reacting PBMC. In most instances, the creation of an escape variant
led to the loss of reactivity indicative of a ‘classical’ immune response. However, some adapted epitopes elicited
higher or equivalent IFN−γ responses compared to the non-adapted epitope, suggesting that the HIV escape may
drive the creation of epitopes that produce ineffectual immune responses that benefit the virus. These results
therefore provide new insights into CD8 T-cell responses against the virus and have implications for HIV vaccine
design.
ACKNOWLEDGEMENTS
We would like to thank the participants of the ACTG 5142/5128 study protocols and the WA HIV Cohort,
Beckman Coulter, “Bill & Melinda Gates Foundation”, National Institutes of Health, National Health & Medical
Research Council and CCIBS staff.
Accredited for compliance with ISO/IEC 17025 interpreted for research using CITAC Guide CG2,
for HLA sequence based typing, viral sequencing and ELISpot analysis. Accreditation number
15785
RESULTS
An epitope was considered immunogenic if it was tested in more than five individuals and was reactive in greater
then 40% of the subjects tested. Using these criteria, ten epitopes with novel HLA-restrictions were identified
primarily from the Nef region of the virus.
The epitope prediction programme, ‘Epi-pred’, also identified sites of potential viral escape in CTL epitopes.
Response to the adapted epitopes together with the non-adapted epitope showed complex patterns of escape.
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HLA Protein Epitope Number of individuals 
tested 
Positive responses 
(%)
Median SFUs/106 PBMCs 
( IQR range)
B*57 Gag RLRPGGKKKY 7 42.86 60 (0 – 280)
Cw*0701 Gag EIYKRWIIM 14 64.29 320 (0 - 475)
Cw*1701 Gag TPQDLNTML 6 66.67 1810 (375 – 2855)
B*2705 Pol KRKGGIGGY 7 85.71 400 (170 - 550)
A*03 Nef SVVGWPAVR 19 57.89 220 (0 - 550)
B*40 Nef MDDPEKEVL 7 42.86 0 (0 - 640)
Cw*0401/Cw*0602 Nef PRYPLTFGW 19/7 47.37/42.86 40 (0 - 300)/0 (0 - 480)
Cw*08 Nef QVPVRPMTYK 11 54.55 320 (0 - 740)
B*1402/Cw*0802 Nef QRQDILDLW 6/7 50/42.86 210 (0 - 630)/0 (0 - 560)
A*3201 Tat NCYCKQCCF 6 50 60 (0 - 300)
Pol   901-909      HLA-B*2705
5’-----HNFKRKGGIGGYSAG-----3’ 690 
SFUs/106 PBMCs
10 
SFUs/106 PBMCs
Non-adapted epitope
Adapted epitope
Classical escape
5’-----HNFKRKGGIGEYSAG-----3’
5’-----DPEKEVLVWKFDSR-----3’
Nef    178-185      HLA-B*1801
2800 
SFUs/106 PBMCs
1900 
SFUs/106 PBMCs
Non-adapted epitope
Adapted epitope
Non-classical escape
5’-----DPEKEVLMWKFDSR-----3’
5’-----ITKGLGISYGRKKRR-----3’
Tat   42-50      HLA-A*0301
900 
SFUs/106 PBMCs
840 
SFUs/106 PBMCs
Non-adapted epitope
Adapted epitope
No difference in responses
5’-----ITKGLGISYGRRKRR-----3’
Gag   20-29      HLA-B*1501
5’-----EKIRLRPGGKKKYKLK -----3’ 560 
SFUs/106 PBMCs
0 
SFUs/106 PBMCs
Non-adapted epitope
Adapted epitope
5’-----PKVSFEPIPSHYCAP -----3’
Env   209-217      HLA-A*0101
740 
SFUs/106 PBMCs
20 
SFUs/106 PBMCs
Non-adapted epitope
Adapted epitope
5’-----EKIRLRPGGRKKYKLK -----3’ 5’-----PKVSFEPIPSIYCAP -----3’
A B C